Protara Therapeutics, Inc. — Director's Dealing 2020

Jan 13, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ArTara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2020-01-09

Reporting Person: Shefferman Jesse (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-09	Common Stock	A	790274	—	Acquired	790274	Direct
2020-01-10	Common Stock	A	50000	$0.00	Acquired	840274	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-10	Stock Option (Right to Buy)	$31.50	A	111250	Acquired	2030-01-09	Common Stock (111250)	Direct

Footnotes

F1: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer.

F2: These shares were received in exchange for i) 4,000,000 shares of ArTara Sub Common Stock; and ii) 142,857 shares of ArTara Sub Exchangeable Common Stock, in connection with the Merger.

F3: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of Issuer's common stock. 25% of the shares vest on each one-year anniversary of January 10, 2020.

F4: 25% of the shares vest on the one year anniversary of January 10, 2020 and 1/48th of the shares vesting monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.